📊 DYAI Key Takeaways
Is DYAI a Good Investment? Thesis Analysis
Dyadic International is a pre-revenue biotech company experiencing severe financial distress with massive operating losses (-224% margin) despite minimal revenue generation ($2.5M). Negative operating and free cash flows (-$3.9M) combined with a narrow equity cushion ($2.6M) create existential runway concerns, making this a high-risk speculative position unsuitable for fundamental analysis.
Why Buy DYAI? Key Strengths
- Adequate liquidity position with $5.8M cash and 2.85x current ratio providing near-term operational runway
- Zero long-term debt eliminating refinancing risk
- Revenue growth of 20.6% YoY indicating early commercial traction in biological products
DYAI Investment Risks to Consider
- Severe operating losses of -$5.7M on $2.5M revenue indicates unsustainable unit economics and business model viability concerns
- Negative free cash flow of -$3.9M will deplete $5.8M cash reserves within 18 months without revenue acceleration or cost restructuring
- Stockholders equity of only $2.6M provides minimal financial cushion; continued losses will rapidly erode shareholder value
- Persistent negative profitability across all margins (-224% operating, -230% net) indicates fundamental business challenges not temporary setbacks
Key Metrics to Watch
- Quarterly revenue trajectory and gross margin achievement as commercial partnerships scale
- Operating cash burn rate and cash runway extension timeline
- Progress toward breakeven on operating basis and path to sustainable unit economics
DYAI Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.85x current ratio provides a solid financial cushion.
DYAI Profitability Ratios
DYAI vs Healthcare Sector
How DYADIC INTERNATIONAL INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DYAI Overvalued or Undervalued?
Based on fundamental analysis, DYADIC INTERNATIONAL INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DYAI Balance Sheet & Liquidity
DYAI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: DYADIC INTERNATIONAL INC's revenue has grown significantly by 108% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.24 indicates the company is currently unprofitable.
DYAI Growth Metrics (YoY)
DYAI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2M | -$203.5K | $-0.01 |
| Q2 2025 | $385.9K | -$1.8M | $-0.06 |
| Q1 2025 | $334.6K | -$2.0M | N/A |
| Q3 2024 | $397.1K | -$203.5K | N/A |
| Q2 2024 | $385.9K | -$956.4K | N/A |
| Q1 2024 | $334.6K | -$956.4K | N/A |
| Q3 2023 | $397.1K | -$956.4K | N/A |
| Q2 2023 | $658.6K | -$956.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DYAI Capital Allocation
DYAI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for DYADIC INTERNATIONAL INC (CIK: 0001213809)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DYAI
What is the AI rating for DYAI?
DYADIC INTERNATIONAL INC (DYAI) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DYAI's key strengths?
Claude: Adequate liquidity position with $5.8M cash and 2.85x current ratio providing near-term operational runway. Zero long-term debt eliminating refinancing risk.
What are the risks of investing in DYAI?
Claude: Severe operating losses of -$5.7M on $2.5M revenue indicates unsustainable unit economics and business model viability concerns. Negative free cash flow of -$3.9M will deplete $5.8M cash reserves within 18 months without revenue acceleration or cost restructuring.
What is DYAI's revenue and growth?
DYADIC INTERNATIONAL INC reported revenue of $2.5M.
Does DYAI pay dividends?
DYADIC INTERNATIONAL INC does not currently pay dividends.
Where can I find DYAI SEC filings?
Official SEC filings for DYADIC INTERNATIONAL INC (CIK: 0001213809) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DYAI's EPS?
DYADIC INTERNATIONAL INC has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DYAI a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, DYADIC INTERNATIONAL INC has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DYAI stock overvalued or undervalued?
Valuation metrics for DYAI: ROE of -222.3% (sector avg: 15%), net margin of -229.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DYAI stock in 2026?
Our dual AI analysis gives DYADIC INTERNATIONAL INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DYAI's free cash flow?
DYADIC INTERNATIONAL INC's operating cash flow is $-3.9M, with capital expenditures of N/A. FCF margin is -155.7%.
How does DYAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -229.6% (avg: 12%), ROE -222.3% (avg: 15%), current ratio 2.85 (avg: 2).